[Changes in antithrombin III, prothrombin fragment 1 + 2 and thrombin-antithrombin III complex following implantation of a coronary Palmaz-Schatz stent].
To detect changes in the clotting parameters antithrombin III (AT III), prothrombin-fragment 1 + 2 (F 1 + 2) and thrombin-antithrombin-III-complex (TAT) after implantation of Palmaz Schatz stents, coagulation was monitored at standardized time points in 35 patients for 10 days. All patients were anticoagulated using a combination of heparin, phenprocoumon, and acetyl salicylic acid. Heparin therapy was guided by APTT levels (normal range 25-35 s), which were still within the therapeutic range (median 49.6 s (25%/75% percentiles 41.6/54.4) on day 10. Simultaneous oral anticoagulation was found to be effective on day 8 on average (INR median 2.24 (1.93/2.50)). The AT III activity dropped significantly (p < 0.0001) after a heparin loading dose of 15,000 IU during stenting. As the heparin dose was reduced on the following days, AT III levels increased significantly (p < 0.0001) during the observation time. There was a highly significant (p < 0.001) negative correlation between AT III and heparin levels. On days 4 and 5 F 1 + 2 values were significantly (p < 0.001 and p < 0.05) higher than on the day of stenting (median 1.07 (0.90/1.31) 1.13 nmol/l and 1.06 (0.85/1.23) nmol/l vs. 0.97 (0.69/1.15) nmol/l) and dropped during anticoagulation. F 1 + 2 levels showed a significant negative correlation (p < 0.0005) with APTT values. TAT values showed no significant changes during the observation period.(ABSTRACT TRUNCATED AT 250 WORDS)
Dittel
M
M
Medizinische Abteilung mit Kardiologie, Krankenhaus Lainz, Ludwig-Boltzmann-Institut für Herzinfarktforschung, Wien, Osterreich.
Haushofer
A
A
Spiel
R
R
Halbmayer
W M
WM
Prachar
H
H
Fischer
M
M
Mlczoch
J
J
D000368:Aged; D000787:Angina Pectoris / Q000097:blood* / Q000628:therapy*; D000925:Anticoagulants / Q000008:administration & dosage*; D000990:Antithrombin III / Q000032:analysis; D001241:Aspirin / Q000008:administration & dosage; D001779:Blood Coagulation Factors / Q000032:analysis*; D005260:Female; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000032:analysis; D010447:Peptide Hydrolases / Q000032:analysis; D010644:Phenprocoumon / Q000008:administration & dosage; D011516:Prothrombin / Q000032:analysis; D015607:Stents; D013927:Thrombosis / Q000517:prevention & control*
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D010446:Peptide Fragments; C046193:antithrombin III-protease complex; C045879:prothrombin fragment 1.2; D000990:Antithrombin III; D011516:Prothrombin; D006493:Heparin; D010447:Peptide Hydrolases; D010644:Phenprocoumon; D001241:Aspirin
Veränderungen von Antithrombin III, Prothrombinfragment 1 + 2 und Thrombin-Antithrombin-III-Komplex nach Implantation von koronaren Palmaz-Schatz-Stents.